Project Grant R01HL183171
Award Date 8/6/26
Completion Date 4/30/31
Dollars Obligated $723K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Washington $264,750 on July 1, 2026, for a Project Grant (R03HL178552) under the Cardiovascular Diseases Research program (CFDA 93.837) to identify pathogenic somatic mutations in pulmonary arterial hypertension. The award funds research to determine whether somatic (acquired) mutations in disease-causing pathways contribute to PAH pathogenesis. The work proceeds through two approaches: analyzing cell-free DNA in circulating...
- The National Heart, Lung, and Blood Institute awarded $1.775 million to Boston Children's Hospital on September 1, 2026, to investigate pericyte-to-smooth-muscle-cell transitions in pulmonary arterial hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses excessive vascular remodeling in pulmonary arterial hypertension by examining how pericytes—specialized mural cells that maintain capillary stability—transition into smooth muscle-like cells under...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $1,540,621 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial inflammation, C-terminal SRC kinase dysregulation, and fibrosis in early pulmonary arterial hypertension. The award funds research into molecular mechanisms regulating fibroproliferative pulmonary vascular remodeling in early PAH, with particular focus on patients with inflammatory...
- The National Heart, Lung, and Blood Institute awarded Brown University $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of chitinase 3-like-1 in pulmonary arterial hypertension pathogenesis. The project grant funds research into how the protein CHI3L1 contributes to immune and metabolic dysfunction underlying vascular remodeling in PAH, with particular focus on macrophage metabolism and pro-remodeling effects. The research...
- The National Heart, Lung, and Blood Institute awarded the University of Maryland, Baltimore $775,687 under Project Grant R01HL183332 on August 10, 2026, to support research on molecular drivers of pulmonary vascular remodeling in pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFPEF). The research investigates beta-2 microglobulin (B2M) as a therapeutic target in PH-HFPEF. The project builds on findings that PH-HFPEF patients display elevated circulating B2M...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Leland Stanford Junior University $165,888 on April 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for Project Grant K08HL183852 to investigate T cell contributions to neointima formation in pulmonary hypertension. The research examines how proliferating T cell lineages and their expressed ligands drive neointimal lesion development in pulmonary hypertension, a fatal disease...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $676,602 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of LYVE1-expressing interstitial macrophage-driven vascular remodeling in pulmonary hypertension. The research examines the role of LYVE1+ interstitial macrophages (IMs) in pulmonary hypertension, a deadly, incurable disease of the pulmonary...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco (UCSF) $1,631,388 on June 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of stress signals in the pathogenesis of pulmonary veno-occlusive disease (PVOD). The project addresses the molecular mechanisms linking loss-of-function mutations in the EIF2AK4 gene to pulmonary vascular remodeling in PVOD, a subclass of pulmonary hypertension...
- The National Heart, Lung, and Blood Institute awarded $237,750 to Trustees of Indiana University (Indiana University Indianapolis) on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for Project Grant R03HL187211 to investigate ATF-5 regulation of mitochondrial function and its role in promoting vascular remodeling in pulmonary arterial hypertension. The research addresses mechanisms underlying vascular cell proliferation and metabolic reprogramming in PAH,...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Vanderbilt University Medical Center $341,280 on September 19, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year mentored career development project investigating apoptosis resistance mechanisms in pulmonary arterial smooth muscle cells. Dr. Niedermeyer, under mentorship from Dr. Larissa Shimoda and Dr. Mahendra Damarla, will conduct hands-on laboratory research, complete...